Pacific Biosciences of California Inc. diskutieren
Pacific Biosciences of California Inc.
WKN: A1C3EQ / Symbol: PACB / Name: PacBio / Aktie / Ausrüstung & Versorgung / Small Cap /
1,55 €
3,62 %
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is now covered by analysts at KGI Securities. They set an "outperform" rating on the stock.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $17.00 price target on the stock.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating and a $11.00 price target on the stock.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating. They now have a $11.00 price target on the stock.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $10.00 price target on the stock, down previously from $13.00.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is now covered by analysts at Stephens. They set an "overweight" rating and a $11.00 price target on the stock.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at UBS Group AG from $12.50 to $12.00. They now have a "buy" rating on the stock.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $9.00 to $7.00. They now have a "buy" rating on the stock.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) was upgraded by analysts at StockNews.com to a "sell" rating.
Ratings data for PACB provided by MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Sanford C. Bernstein from $9.00 to $2.50. They now have an "outperform" rating on the stock.
Ratings data for PACB provided by MarketBeat
Neueste Beiträge
DA_Davidson in Douglas Dynamics Inc. diskutieren